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Background: Research has shown that individuals with schizophrenia use caffeine at higher rates than the general
population; however, no qualitative research has been undertaken investigating problematic caffeine use and its
effects on this population. This article explores the role of caffeine consumption in the lives of people with schizophrenia
through a narrative analysis of the attitudes and beliefs associated with this practice, and how these, in turn, influence
caffeine consumption.
Methods: A qualitative study was undertaken with individuals who had previously scored in either a ‘moderate’ or ‘high’
risk category for caffeine use on the Alcohol, Smoking and Substance Involvement Screening Tool (ASSIST).
In-depth interviews were undertaken with 20 individuals, and transcripts were analysed thematically to identify
prominent perspectives.
Results: Consistent with previous literature, participants’ caffeine consumption was driven largely by its
stimulating properties; however, participants also identified ‘cravings’ as an important motivating factor.
Participants’ behaviours related to caffeine consumption seemed to be tempered by their previous experiences
of consumption; if participants had experienced positive effects such as alertness or relaxation in the past, their
use was maintained at a similar level or increased. Conversely, participants who anticipated negative
consequences often altered their patterns of caffeine consumption; for example, by substituting caffeinated
drinks that minimised or ceased their experience of negative side effects for those that directly caused such
impacts. Overall, participants largely identified caffeine consumption as a highly meaningful activity, which
provided structure to their day and facilitated opportunities for social interaction.
Conclusions: The inconsistencies between individuals’ beliefs about their health and the actual risk of harm associated
with health-related behaviours present significant and ongoing challenges for the implementation of relevant
and effective strategies for health promotion among individuals diagnosed with mental illness. As a starting
point, it would be worthwhile for services engaging with people diagnosed with mental illness, and in particular
schizophrenia, to consider implementing caffeine-related health literacy strategies to educate consumers about
the risk of excessive caffeine consumption and the interactions between caffeine and antipsychotic medications.
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Caffeine is the world’s most widely used stimulant and is
perceived to have a number of positive effects, including
reduced fatigue, relaxation, and increased alertness [1].
Caffeine use of 500 mg per day and over (four to seven
standard cups of coffee, or seven to nine cups of tea) is
considered a ‘significant health risk’ and has been associ-
ated with the exacerbation of symptoms of mental illness
[2,3]. Further, a significant relationship between caffeine
consumption and dose of antipsychotic medication has
been identified [4,5], with some studies suggesting a link
between chronic caffeine consumption and the likeli-
hood of experiencing negative side effects from medica-
tion [6].
In line with these findings, the suggestion that individuals
with a mental illness consume caffeine at significantly
higher levels than the general population is particularly
concerning [6-8]. Larson and Carey [9] reported that their
sample of psychiatric outpatients with a diagnosis of schizo-
phrenia consumed seven times more caffeine than the gen-
eral population, whereas other studies have reported mean
daily caffeine intake among people with schizophrenia of
between 400 - 471 mg [6,10]. In comparison, Brown and
colleagues [11] reported a main daily caffeine intake of be-
tween 288 – 426 mg in a random sample of 481 adults
from the general population in Ontario, Canada.
A recent study by Zimmermann and colleagues [12] ex-
plored substance use among consumers of an Australian
community mental health service and found high rates of
potentially problematic caffeine consumption. Zimmermann
et al. [12] reported that 78.9% of participants were placed
in a ‘moderate’ risk category and 7.4% in a ‘high’ risk cat-
egory based on their caffeine use according to the Alcohol,
Smoking and Substance Involvement Screening Tool
(ASSIST) [13]. Overall rates of caffeine use were higher
than all other substances screened as part of the study,
including tobacco, alcohol and cannabis [12]. Within this
study, problematic caffeine use was also found to be more
common in individuals with a diagnosis of schizophrenia,
as compared to other diagnoses. However, a limitation of
the study was a lack of detailed information gathered on
the specific behaviours of individuals related to their use
of caffeine and in-depth exploration of the motivations
and context framing their caffeine consumption.
Various theories have been proposed to explain elevated
levels of caffeine consumption among individuals with a
serious mental illness; including self-medication to treat
symptoms such as anhedonia, drowsiness, and issues with
concentration [14]; and to counteract the side effects of
antipsychotic medications which can present in a similar
way to the abovementioned symptoms [9]. However, few
studies have explored caffeine use among individuals diag-
nosed with mental illness living in the community. We
identified only one previous qualitative study of the use oflegal drugs by individuals diagnosed with a range of mental
illnesses, in which focus groups were conducted to explore
the function of substances that included caffeine, nicotine
and alcohol [2]. While the authors reported that psychiatric
outpatients in their sample consumed caffeine to en-
hance arousal and to counteract the side effects of
medication, such as drowsiness and dry mouth, the au-
thors did not specifically focus on the experiences of
individuals with schizophrenia.
The current study was undertaken to better understand
the nature of caffeine use and its effects among individuals
with schizophrenia using a qualitative approach. Qualitative
designs are highly useful in exploratory studies with min-
imal previous research to draw upon [15]. The data present
a first-person phenomenological account of caffeine con-
sumption to better understand the subjective meanings
associated with caffeine use among this group [16]. We ex-
plore qualitative differences in how participants experience
and derive meaning from caffeine consumption, including
individuals’ perceptions of their capacity to make changes
to these behaviours, and describe the divergence of atti-
tudes about, and motivations for, caffeine consumption
through participants’ construction of a larger dialogue
around the actual and potential harms of regular caffeine
consumption.
Methods
The current study was conducted across 10 Neami
National sites operating in Melbourne, Victoria. Neami
National, a community managed mental health organ-
isation, provides rehabilitation and recovery support for
people with a serious mental illness. A mixed methods de-
sign was implemented which involved the administration of
a caffeine use questionnaire and in-depth interviews with a
subset of the larger sample. This article draws on the find-
ings of the in-depth interviews.
Consumer information was extracted from Carelink +
(the internal consumer database) to identify consumers
who had previously received a clinical diagnosis of
schizophrenia or schizo-affective disorder (based on in-
formation from the referring clinician), and whose caffeine
use scored in the categories of ‘moderate’ or ‘high’ risk ac-
cording to ASSIST criteria [13]. The ASSIST is used rou-
tinely in clinical settings to indicate the presence of abuse
and dependence symptoms and substance-related prob-
lems, supporting treatment outcomes by identifying indi-
viduals who might benefit from further assessment and
intervention [17]. The ASSIST is routinely administered to
all consumers across Neami National as it identifies a range
of problems associated with substance use including acute
intoxication, regular use, dependence or ‘high risk’ use and
injecting behaviour. A Specific Substance Involvement (SSI)
score is calculated which indicates the level of risk associ-
ated with the use of a particular substance, with high risk
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pendence or is currently dependent on the substance, and
is likely experiencing a range of issues as a result of their
substance use [13].
Those consumers who were deemed eligible to partici-
pate based on their SSI scores were invited to complete
the caffeine use questionnaire and undertake an in-
depth interview with the research team after providing
informed consent to participate in the study. The ques-
tionnaire administered by Neami support workers was
designed to collect demographic information including
information pertaining to comorbid disorders. This in-
formation was self-reported by participants; no clinical
assessments were completed with participants to corrobor-
ate this data. The questionnaire also collected detailed in-
formation about individuals’ caffeine consumption patterns,
their beliefs about the short and long-term risks associated
with caffeine and their general health. In total, caffeine
use questionnaires were completed by 59 individuals with
schizophrenia or schizo-affective disorder between March
and June 2012, and 40 individuals consented to be con-
tacted for an in-depth interview, of which 20 were under-
taken. Those who chose not to participate in interviews did
so for a range of reasons, including experiencing acute ill-
ness or crisis; perceiving the questions as being too invasive;
and reporting that they were not currently consuming as
much caffeine as they had been previously.
Interviews were undertaken by LT and AZ, who both
had no pre-existing relationship with participants. Inter-
views were semi-structured, and interviewers began by
asking participants to describe a ‘typical day’ involving
caffeine use, including frequency, amount and types of
caffeinated drinks, when they used caffeine (i.e. shortly
after waking; only during the day; all day; only at night),
and whether they combined caffeine with other sub-
stances e.g. food, alcohol, cigarettes. If participants did
not spontaneously provide the following information
while describing a typical day of caffeine consumption,
they were prompted to discuss: their reasons for con-
suming caffeine; experience of positive or negative side-
effects both short- and long-term; attempts (if any) to
decrease or cease consumption; perceptions of risk re-
lated to caffeine use, and perceived risk of caffeine use
compared to other stimulants. Interviews were con-
ducted in locations of convenience to the participant, in-
cluding private homes, a local café, or their Neami site.
By the twentieth interview, a saturation point had been
reached where very little new information was being
elicited, and so a decision was made to discontinue
interviewing [18]. The interviews were recorded on a
digital recorder and transcribed verbatim by an external
organisation.
Thematic analysis was deemed the most appropriate
method for interpreting interview data as themes can beconstructed inductively and without reliance on a pre-
determined theoretical paradigm, thus making it highly
useful in exploratory studies with minimal previous re-
search to draw upon [15]. Analyses were conducted
using NVivo 9 (QSR International, Victoria, Australia)
by three researchers (LT, AP, AZ). At least two researchers
coded each interview, and thematic categories were firstly
constructed inductively from interview data by all three
researchers independently of each other [19]. Following the
analysis process, LT AZ and AP met to compare their cod-
ing of the themes. The minor differences identified were
discussed and negotiated until consensus was reached.
During analysis, it became apparent that caffeine con-
sumption behaviours were underpinned by participants’
beliefs of the risk of harm associated with caffeine use.
The following sections explore in greater detail the na-
ture of caffeine consumption among participants and
the ways in which their beliefs and expectations about
caffeine use shaped their behaviour.
Ethical considerations
The project had ethical approval from the Eastern
Health Human Research Ethics Committee. Participants
were informed about the purpose of the study, their
right to refuse to participate without any adverse impact
on their support or relationship with the organisation, as
well as measures to ensure confidentiality; including using
a numerical ID and removing any personal or identifying
details from their interview transcripts. After this explan-
ation, participants provided written consent to participate
in the study.
Results
Description of the sample
Participants were aged between 29 and 61 years, with an
average age of 42 years; seventeen men and three women
took part; and 17 participants were born in Australia. The
three participants born outside of Australia reported their
countries of origin as Vietnam, England and Italy. None
of the sample participants identified as being Aboriginal or
Torres Strait Islander. Two participants had a diagnosis of
schizo-affective disorder, and eighteen had a diagnosis of
schizophrenia. The main antipsychotic medications that
participants reported being prescribed were clozapine,
olanzapine and paliperidone.
Forty percent of interview participants reported ex-
periencing current issues with alcohol and/or other
drugs, with 12 identifying as regular smokers, smoking
an average of 21 cigarettes per day (eight of these indi-
viduals reported smoking a pack of 25 or more per day).
In relation to other substance use as identified by SSI
scores on the ASSIST, 15 participants were identified as
being in a ‘moderate’ or ‘high’ risk category for tobacco
(11 and four respectively); six in a ‘moderate’ or ‘high’
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in a ‘moderate’ risk category for cannabis; and one in a
‘moderate’ risk category for opioids. This is consistent
with previous studies that suggest that a significant pro-
portion of people diagnosed with serious mental illness
have comorbid substance use disorders [20].
Participants’ SSI scores for caffeine revealed that the
majority fell into a ‘moderate’ risk category (eighteen
people), while two participants were in a ‘high’ risk
category. These scores were highly representative of
the larger sample that completed caffeine use question-
naires. Other than issues relating to substance use, par-
ticipants did not report any co-morbid mental health
disorders.Patterns of caffeine consumption
For the majority of participants, caffeine consumption
began in the morning shortly after waking and contin-
ued throughout the day. More often than not, partici-
pants began their mornings by consuming either coffee
or tea. Caffeine consumption in the morning was par-
ticularly meaningful for participants and was framed as a
“rich ritual” that enabled individuals to ease into their day.
Only one participant drank caffeine almost exclusively in
the evenings. On average, participants consumed 2.4 differ-
ent types of caffeinated drinks in any given week, including:
Coca-Cola (fifteen people), instant coffee (twelve), tea (six),
brewed coffee (four), iced coffee (three), and energy drinks
(two). Eight participants reported consuming three or more
different types of caffeinated drinks in any given week.The place of caffeine in participants’ lives
Two distinct groups of caffeine consumers emerged
from the interviews. The first group saw their caffeine
consumption as a trivial issue and did not see the rea-
son for the strong focus of questioning about caffeine.
For example: “I don’t know why [I drink caffeine], I
think just boredom and things like that”. The second
group were much more aware of their caffeine use and
were able to articulate their reasons for use. These par-
ticipants described the important role of caffeine in
their lives and had clearly reflected on their caffeine
use in the past. For example, one participant referred
to caffeine as “food for the soul”, whereas another con-
sidered it “one of the simple pleasures of life”. Many of
the second group’s narratives described the ritualistic
nature of their caffeine consumption. More often than
not, it was framed as a habit that had developed over a
considerable period of time, often beginning in child-
hood. Some participants could not imagine life without
caffeine and discussed their caffeine use as essential for
daily functioning. These participants framed their caf-
feine use more in terms of addiction or dependence.Dependence and craving
While no direct measures of abuse/dependence were ad-
ministered among interview participants, the average
caffeine consumption of coffee drinkers within the sam-
ple was 523 mg per day (which is considered a ‘signifi-
cant health risk’ [2,3]), and half of participants reported
feeling that they had minimal control over their caffeine
consumption, with some indicating an inability to live
without caffeine. For example:
“I was vampirical [sic] on coffee like just drinking it
like it was my life source”.
“I don’t miss cigarettes either, but coffee, I have to
have coffee…I don’t think I could live without coffee”.
“I’d be lost without my Coca Cola. I couldn’t survive
without it…I can’t get off to sleep without it…I need
to have a certain amount each day to get me
through”.
Other participants were less emphatic in their responses,
but still expressed feelings of needing or wanting caffeine:
“I just felt like I needed it…If I didn’t have a cup of
coffee in the morning or something I felt a bit dizzy”.
“It’s addictive and I just enjoy it…I bought tea a few
weeks ago and I tried to replace a tea for a coffee, I
found it very hard…I’d like to not be as dependent on
it, but it’s just a natural thing just to wake up, put the
jug on, make a cup of coffee”
For the abovementioned participant, the need to con-
sume caffeine overrode the sub- optimal conditions of her
accommodation in which to prepare caffeinated drinks:
Participant: I’ve tried cutting down, but that’s a waste
[of money]… and the thought to have it was just too
strong. So I wake up at say nine, have breakfast then I
go straight to my room and I have two or three
coffees. Interviewer: Is there a reason why you drink
two or three in a row as opposed to just one?
Participant: I think because I get water from the hot
water tap, it’s not really hot water, it’s lukewarm.
Interviewer: OK is there any reason why you don’t use
a kettle? Participant: We’re not allowed to have
them…for safety reasons.
Benefits of caffeine use
The stimulating properties of caffeine were one of the
primary motivations for morning consumption; many
people enjoyed the “boost” and the “buzz” from caffeine.
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lethargic waking up and all that sort of stuff, but then I
put on the kettle as soon as I wake up”. This appeared
to be an experience shared by the majority. Some partic-
ipants used caffeine for relaxation. For example, one
participant almost exclusively consumed coffee in the
evenings as a way to “chill out” in the same way that an-
other person might drink alcohol: “I wouldn’t call my-
self a coffee, caffeine addict, but yeah I don’t mind
having a couple of…oh like probably in the night, I don’t
know five cups or something”. Others consumed caffeine
throughout the day and used caffeine as a reward or used
their caffeine break as a way to disrupt their routine, for
example:
“It gives me a bit of time out…A break from the
pressures of the day”.
“When I’m working I have a coffee after about two or
three hours, just to fill in, as a break”.
“Yeah it’s sort of like a luxury thing, yeah you just feel
like it”.
Some participants were staunch advocates for caffeine
and looked for ways to justify their use. For example,
one participant said they had “heard on the news the
other day that people who drink coffee live longer…I
thought I’m coming to see you today, I’ll remember to
mention the fact that coffee drinkers live longer”.
The majority of respondents reported consuming caf-
feine, at least in part, for its pleasurable taste. In particular,
the sugary taste was identified by participants as an import-
ant factor in their enjoyment of caffeinated drinks. Some
participants chose soft drinks, instant coffee and iced coffee
over brewed coffee for this reason:
“You can’t kill it [brewed coffee] with sugar like the
other stuff…I prefer instant, the instant stuff ’s smaller,
you know more smooth and creamy as opposed to the
others”.
“[Iced coffee is] a bit sugarier and tastier [than instant
coffee] and moorish is probably the right word for it”.
“I like the sweetness in the Coca Cola, the sugar
and that”.
However, some participants also continued to con-
sume caffeine even though they reported not enjoying
the taste; for two individuals the perceived benefits of
caffeine overrode their distaste for the drink. There
was a strong link between drinking caffeine and smok-
ing cigarettes, consistent with previous research [7,21,22];irrespective of whether participants were current or former
smokers, there was a general sense that caffeine and nico-
tine “go hand in hand…combined, they both taste good”.
Previous literature suggests that caffeine ingestion increases
reinforcement from nicotine [21-23], and that caffeine use
may be a contributing factor in the onset, maintenance of
or relapse to tobacco dependence [21], which may provide
some explanation for the high rates of concurrent caffeine
use and smoking among participants.
The final motivation for caffeine use cited by partici-
pants was the social aspect of consumption. It is well
documented within the literature that people with a
diagnosis of psychotic illness experience issues around
interpersonal relationships and loneliness [24-26] so it is
unsurprising that almost half of participants cited the so-
cial aspects of caffeine consumption as being a primary
motivator for their behaviour:
“[Drinking caffeine during childhood] was about
bonding with my mum…having a coffee and a biscuit
and stuff”.
“Once or twice a week I go for a coffee with my
friend… I usually ring up a friend and go for a coffee
and have a chat”.
“It’s just such a nice social thing. The Italians do it
and the Greeks do it…it’s like when you go to
someone’s house, do you want a cuppa? My friend
comes each night and we have a coffee, a biscuit, then
dinner…People meet and greet over coffee, friends,
old friends and family, you know”.
“In the hospital…with people with mental illness it’s a
sort of a starting point, it’s a social thing, you know
cigarette, bottle of coke and when you speak to other
people with mental illness you know it revolves
around cigarettes and Coca Cola”.
A number of participants couched their caffeine con-
sumption in terms of caffeine’s perceived social accept-
ability compared to other substances such as alcohol or
cannabis. It appeared as though social perceptions about
caffeine played a significant role in participants’ deci-
sions about consumption, particularly around being seen
to be “trendy” or “fashionable” by others. The desire to
be perceived in a certain way through the consumption
of caffeine within a social context might relate to the
challenge of social inclusion for people experiencing en-
during mental illness.
Perceptions of caffeine compared to other drugs
Participant’s perceptions of their caffeine use were in-
fluenced by the social positioning of caffeine use as a
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licit and illicit substances, namely alcohol, cannabis,
cocaine, methamphetamine and heroin, but most still
considered caffeine to be a stimulant, “like a drug”:
“Amphetamines are far stronger, but it [coffee] does
do that, it makes you race a bit…The coffee sort of
makes you feel like you’re on speed”.
“I do perceive it as a stimulant but I wouldn’t perceive
it as something that could create that much harm
unless it was taken in extreme amounts”.
“I don’t see it as a big deal… I know a lot of people
who have no addiction or anything to it”.
“I don’t even think it comes even close [to illegal
drugs]… it’s legal, it’s normal as far as I’m concerned.
Yeah it might have you know the side effect of
keeping you awake or more alert whatever they’re
saying about coffee, but I would never even put it in
the same category as drugs like that”.
“Well it’s definitely not the worst [substance]…things
like alcohol and other drugs are a lot more damaging
than caffeine”.
These perceptions of caffeine compared to other sub-
stances seemed to temper participants’ responses about
their expectations of the risk of harm associated with
consuming caffeine. With the exception of a few individ-
uals who had experienced significant impacts on their
physical or mental health, participants generally regarded
caffeine as one of the ‘safer’, more socially acceptable
substances that they could be consuming.
Negative effects of caffeine
Few participants expressed concerns about their caffeine
consumption in terms of either short or long-term
harms. However, when prompted, a number of partici-
pants reported experiencing negative side effects from
what they considered excessive caffeine consumption,
including experiencing dry mouth; insomnia; bloated
stomach; blurred vision; anxiety; hallucinations; nausea,
and vomiting. For most, the experience of these side ef-
fects was not significant enough to elicit a change in
their consumption. In fact, many participants had not
experienced negative side effects and did not believe that
caffeine was harmful. Those who stated concerns about
caffeine were most often in relation to the consumption
of soft drink as opposed to coffee.
A small group (three people) perceived caffeine to be a
potentially harmful drug and framed their caffeine con-
sumption in terms of attempts to cut down or quit. Someparticipants explicitly discussed their recent efforts to cut
down or cease their caffeine consumption; however, al-
most all of these individuals had returned to their previous
levels of consumption. For example:
Participant: If I do things like go to the gym after I’ve
had some tea like I did yesterday, it affected me after
the gym. I start hearing voices and get a fair bit of
anxiety and stuff like that… I don’t know whether I’m
addicted to it or…I also like the taste of Pepsi Max so
much I, I’d like to still be able to drink it, but I’ve cut
down since [realising it was contributing to psychosis]
I haven’t had any Cola for a little while… Interviewer:
So when you say you don’t know if you’re addicted
to it, what would… How do you think that that
would look?
Participant: I guess you’d, you’d want to be drinking it
every day…Which I’m doing pretty much, but I mean
because of the psychosis yesterday I didn’t have any.
This participant had also ceased consumption of coffee
as it was contributing to his experience of psychosis:
Interviewer: And what about coffee, you’ve never
liked the taste of coffee?
Participant: No I love the taste, but I just went off it
because it was affecting me [increasing frequency of
psychosis] too much…It sort of got stamped in my brain
I guess that if it was coffee then no matter how strong it
was, whether it was normal coffee or a decaf, it just
stamped in my brain that it was going to affect me.
One participant recounted that their high levels of caf-
feine consumption had affected their physical health to
the point that they had recently been admitted to hos-
pital, but had since been able to decrease their consump-
tion. This participant did not specify what their physical
health condition was, but stated that:
“I was drinking it [instant coffee] all day…right up to
about eight o’clock at night and I couldn’t control
myself. I just for some reason couldn’t control myself
and that so eight o’clock at night would be my last
coffee and then during the night I felt like I couldn’t
sleep because of it…I was also drinking probably four
or five 1.25 litre [bottles] a day…I ended up in
hospital for five days, because the fizzy drinks blew,
blew my tummy up a lot…I had a tube up my nose
and back down my throat and yeah”.
The experiences outlined above represented the most
significant impacts on participants and were indicative
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crease or cessation of caffeine consumption.
Most participants stated a preference for caffeinated
drinks with high sugar content or that tasted ‘sugary’;
however concurrently expressed an awareness of the po-
tentially harmful effects of sugar on their physical health.
A handful of participants had changed their consump-
tion practices as a result of this perceived risk:
“Sometimes I had one 1.25 Litre bottle of normal
Coke and I thought oh this tastes great and hang on a
sec I shouldn’t have drunk that because of the sugar
and yeah I changed. Yeah that full on sugar rush is
not very good for me”.
In general, though, participants were uninterested in
changing their level of sugar consumption unless a trusted
authority e.g. General Practitioner made a recommendation
to that effect.
Caffeine and interactions with medication
Some participants consciously reflected on the inter-
action between caffeine use and their medication. For
example, one participant suggested that drinking caffeine
“will actually help break down medication…research says
that four or five coffees a day actually help your liver
function”. This participant reported that:
“When I was taking hard tabs [of antipsychotic
medication], I’d have a couple of coffees to whack it
down [sic] in my bloodstream…If I was taking a lot
of hard tablets I would probably consume more
Coca-Cola or coffee to break it down”.
This participant believed that caffeine consumption
improved their liver function, and believed that the
stronger the dose of medication they were taking, the
more caffeine they would need to consume to metabol-
ise it. Further, other participants emphasised the import-
ance of caffeine consumption to counteract the sedation
that they experienced after taking medication: “Cloza-
pine makes me quite drowsy, so when I wake up in the
morning…those first cups of coffee are really handy”.
Others had noticed that caffeine consumption had an
impact on the effectiveness of their medication, but
found it difficult to verbalise the specific interaction with
caffeine:
“It’s probably not the best habit to have, drinking too
much [coffee] because I do think it does keep you
awake far longer than you should…I don’t know for
certain how it effects the medication, but I do think
that there’s…it’s a definite yes as far as the
effectiveness of it [medication]… Because like I said,when I have taken it, even when I’m exhausted I’ve
already probably drank four or more coffees than I
probably usually would and there’s still that agitation
and not as easy to get to sleep. Whereas if I stick to
what I usually do, within half an hour of taking the
medication it’s pretty much guaranteed that I’m gonna
[sic] be falling asleep”
“I’ve been on Seroquel and stuff like that and when I
was drinking coffee and taking that medication, it
triggered like…it had a very stimulating effect, I
thought it was maybe to do with combining the
medication and coffee”.
“You see with clozapine it puts me to sleep regardless
of the caffeine I drink during the day…but I was also
told, the doctor told me once that drinking Coca Cola
can affect the levels of clozapine in your blood”.
Even though participants’ reflections did not all con-
cord with previous research around interactions between
caffeine and antipsychotic medication, it was noted that
participants were aware of psychological and physio-
logical changes associated with medication use and caf-
feine consumption, even though close to eighty per cent
of the larger sample of 59 participants stated that no-
one had told them about possible interactions. The sug-
gestion by some participants that they noticed changes
in the effects of their medication based on their caffeine
consumption indicates that further research into these
interactions is warranted, particularly in light of recent
clinical studies, which provide evidence of a robust effect
of caffeine on decreasing serum clozapine levels among
some individuals [27,28].
Discussion
To our knowledge, this article is only the second qualitative
study aimed at understanding the role that caffeine plays in
the life of people with serious mental illness, and the first
qualitative study attempting to understand caffeine use
among people with schizophrenia. Our analysis revealed
that the patterns of, and motivations for, caffeine consump-
tion among our sample were varied. In particular, two
divergent narratives emerged from the interviews, with par-
ticipants offering opposing viewpoints about caffeine’s po-
tential for harm. The first group constructed their caffeine
consumption as a trivial issue, one that posed no risk of
harm to their physical or mental health. Participants in this
group either perceived their caffeine use as a non-issue or
cited perceived benefits and/or positive effects of consum-
ing caffeine. Accordingly, this group reported little to no
desire to make changes to their caffeine consumption.
On the other hand, a smaller group acknowledged either
potential or actual harms that they had experienced as a
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soft drinks (as opposed to coffee). This group also ac-
knowledged the benefits of caffeine use, but were more
likely to frame their consumption in terms of addiction or
dependence.
Participants’ behaviour appeared to be driven by ex-
pectations about caffeine consumption based on previ-
ous experiences and perceived feelings of control over
their patterns of use. If participants had experienced
positive effects from caffeine consumption in the past,
such as relief from boredom, or increased alertness,
participants reported positive beliefs about caffeine con-
sumption and their use was maintained and often in-
creased, as they did not perceive themselves to be at serious
health risk. This seemed particularly relevant for partici-
pants who framed their use in terms of dependence: con-
suming caffeine at consistent or increasing levels gratified
feelings of ‘needing’ or ‘wanting’ caffeine, or mitigated side
effects ostensibly as a result of caffeine withdrawal, thus
perpetuating the behaviour through the anticipation that
consuming caffeine would prevent such negative conse-
quences in future.
Conversely, participants who anticipated negative con-
sequences often altered their patterns of caffeine consump-
tion. The degree of behaviour modification appeared to
vary according to the severity of the harm that participants
anticipated occurring as a result. Participants who had pre-
viously ceased consuming a type of caffeinated drink due to
anticipated harm often substituted other types of caffein-
ated drinks. For example, one participant was hospitalised
as a result of excessive soft drink consumption and began
drinking coffee after discharge from hospital as this form of
caffeine did not cause gastrointestinal upset. As outlined
above, one participant stopped drinking coffee and cola as
these drinks exacerbated their psychosis and began drink-
ing tea as it had less of an impact on their symptoms. In
this respect, participants who anticipated negative conse-
quences from caffeine altered their behaviour in line with
their previous experience to achieve an ‘ideal’ level of caf-
feine consumption that they anticipated would maximise
positive affect and minimise harm. This also appeared to be
true of participants’ perceptions of risk associated with
sugar consumption, although participants seemed more
willing to abide by the advice of a trusted professional if
they believed their health to be at risk.
Overall, participants’ decision making around caffeine
consumption (based on the risk of harm and perceived
social desirability) appears similar to the hypotheses for
these behaviours offered by previous studies [2,9]. These
studies suggest that individuals with a mental illness largely
consume caffeine to self-medicate and reduce side effects
of medication. Participants from both studies identified ‘in-
creased alertness’ and ‘taste’ as a factor that influenced their
caffeine consumption. Significantly more participants fromthe current study than the study by Carey et al. [2] identi-
fied cravings (expressed as needing or wanting caffeine)
as a motivating factor for consumption. It is unknown
whether these motivations are consistent with those of the
general population, as we were unable to identify any quali-
tative studies that have explored these factors among com-
munity samples.
Further, that participants noticed and described an inter-
action between caffeine consumption and antipsychotic
medications corroborates the findings of clinical studies
which suggest that caffeine can impact on serum clozapine
levels [27,28]. Further research would better illuminate
the complex interactions between caffeine consump-
tion and antipsychotic medications, especially given
the prevalence of (often excessive) caffeine consump-
tion among this group.
Participants expressed a preference for, and a tendency to
consume caffeinated drinks with high sugar content; and
most often combined caffeine with cigarettes. Participants’
comments about the sugar content of their preferred caf-
feinated drinks were consistent with previous literature in-
dicating that people diagnosed with schizophrenia consume
sugar at levels significantly higher than World Health Or-
ganisation recommendations [29,30].
These findings, when considered together, contribute
to the body of evidence suggesting a link between sugar,
tobacco and caffeine [4,21-23], and as such, future re-
search could investigate the influence of sugar and to-
bacco smoking on caffeine craving, particularly among
individuals diagnosed with mental illness.
Limitations
Intentional sampling was used to recruit participants; if
participants had been selected randomly, this may have
elicited greater variation in results and thus represented
a more diverse range of perspectives. Further, since par-
ticipants were recruited from one specific service type
within a single state, it is likely that the findings cannot
be generalised to the wider population. Reliance on partici-
pants’ recall of caffeine use, rather than objective measures,
potentially limits the validity of the data. Consideration
should be given to the potential for participants’ short-term
memory to be compromised by impairments which are
commonly held features of schizophrenia [31]. To over-
come this issue, future research might benefit from utilising
ecological momentary assessment tools to enable partici-
pants to report on symptoms, affect and behaviour in close
to real time [32].
Nevertheless, the current study was largely explorative
in the sense that only one previous study could be iden-
tified that targeted a similar population; even then, the
level of detailed analysis was insufficient to draw paral-
lels with the findings from the current study. Given that
previous research into the short and long-term impact
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ings, further research to assess the risk of harm associ-
ated with interactions between psychotropic medications
and caffeine is warranted.Conclusions
Numerous studies have linked excessive caffeine con-
sumption with negative effects on physical and mental
health [2-6]. However, as responses from participants
within the current study indicated, the inconsistencies be-
tween individuals’ beliefs about their health and the actual
risk of harm associated with health-related behaviours
present significant and ongoing challenges for the imple-
mentation of relevant and effective strategies for health
promotion among individuals diagnosed with mental
illness. As a starting point, it would be worthwhile for
services engaging with people diagnosed with mental
illness, and in particular schizophrenia, to consider
implementing caffeine-related health literacy strategies to
educate consumers about the risk of excessive sugar and
caffeine consumption and the interactions between caffeine,
tobacco, sugar and antipsychotic medications. Given the
number of participants within the current study who
strongly endorsed the benefits of caffeine consump-
tion, the challenge of engaging consumers in strategies
around modifying caffeine consumption will no doubt
be ongoing. Nevertheless, addressing excessive caffeine
consumption is an important component of improving
long-term physical health outcomes for individuals
diagnosed with serious mental illness.
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